Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update
Provided By GlobeNewswire
Last update: May 14, 2025
FHD-909 (LY4050784) advancing in Phase 1 dose escalation trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population
Read more at globenewswire.com
